Jazz Pharmaceuticals JAZZ Epilepsy — Revenue from Contract with Customer, Excluding Assessed Tax

Other product segments

Similar metrics at other companies

ETROther revenues — Revenue from Contract with Customer, Excluding Assessed Tax

$36.28M-41.5%

KMXService revenues — Revenue from Contract with Customer, Excluding Assessed Tax

$24.2M+24.1%

TNLAncillary Revenues — Revenue from Contract with Customer, Excluding Assessed Tax

$0-100%

TNLTransaction Revenues — Revenue from Contract with Customer, Excluding Assessed Tax

$109M-6.8%

QSRProperty revenues — Revenue from Contract with Customer, Excluding Assessed Tax

$0-100%

NTRSOther — Revenue from Contract with Customer, Excluding Assessed Tax

$68.6M+8.2%

FAQ

What is Jazz Pharmaceuticals's epilepsy — revenue from contract with customer, excluding assessed tax?

Jazz Pharmaceuticals (JAZZ) reported epilepsy — revenue from contract with customer, excluding assessed tax of $249.8M in Q1 2026.

What does epilepsy — revenue from contract with customer, excluding assessed tax mean?

This metric represents the total net revenue generated from the sale of pharmaceutical products specifically indicated for the treatment of epilepsy and related seizure disorders. It reflects the commercial performance of the company's neurology portfolio, primarily driven by cannabinoid-based therapies, after accounting for returns, rebates, and other sales deductions. This figure is a critical indicator of the company's market penetration and therapeutic adoption within the specialized epilepsy treatment landscape.